Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.

Jason R FangusaroDuane A MitchellMehmet KocakGiles W RobinsonPatricia Ann BaxterEugene I HwangJianping HuangArzu Onar-ThomasIra J DunkelMaryam FouladiKatherine E Warren

Published in: Pediatric blood & cancer (2020)

The MTD of pomalidomide is 2.6 mg/m2 . It was well tolerated, and immune correlates showed a serum immune response. These data led to an industry-sponsored phase 2 trial of pomalidomide monotherapy in children with recurrent brain tumors (NCT03257631).

Keyphrases

multiple myeloma
immune response
young adults
open label
multiple sclerosis
clinical trial
study protocol
electronic health record
randomized controlled trial
combination therapy
machine learning
toll like receptor